• No results found

Cross-reactive neutralizing humoral immunity in HIV-1 disease: dynamics of host-pathogen interactions - Publications

N/A
N/A
Protected

Academic year: 2021

Share "Cross-reactive neutralizing humoral immunity in HIV-1 disease: dynamics of host-pathogen interactions - Publications"

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)

UvA-DARE (Digital Academic Repository)

Cross-reactive neutralizing humoral immunity in HIV-1 disease: dynamics of

host-pathogen interactions

van Gils, M.J.

Publication date

2011

Link to publication

Citation for published version (APA):

van Gils, M. J. (2011). Cross-reactive neutralizing humoral immunity in HIV-1 disease:

dynamics of host-pathogen interactions.

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

(2)

262

l

IsTofpublIcaTIons

van Gils, M.J., Euler, Z., Crooks, E.T., Decker, J.M., Gray, E.S., Tumba, N., Lynch, R.,

Mascola, J.R., Binley, J.M., Shaw, G.M., Morris, L., and Schuitemaker, H., Neutralizing activity against both gp120 and gp41 in patients with HIV-specific cross-reactive neutralizing humoral immunity. (Manuscript in preparation)

Wahren, B., Brinckmann, S., da Costa, K., Raue, K., Hallengard, D., Klein, K., Mainetti, L., Palma, P., Reudelsterz, M., Seifried, J., Skold, A., van Gils, M.J., Ruffin, N., Shafer, K.,

Sheik-Khalil, E., Uchtenhagen, H., Vabret, N., Ziglio, S., Reinhart, D., Shattock, R., and Gotch, F., Rational Design of HIV Vaccine and Microbicides: Report of the EUROPRISE Annual Conference 2010. (Manuscript in preparation)

van Gils, M.J., Bunnik, E.M., Boeser-Nunnink, B.D., Burger, J.A., Terlouw-Klein, M.,

Verwer, L.E.N.I., and Schuitemaker, H., Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. (Submitted for publication)

van Gils, M.J., Edo-Matas, D., Burger, J.A., Bowles, E.J., Stewart-Jones, G.B., and

Schuitemaker, H., Redirected evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum. (Submitted for publication)

van Gils, M.J., and Schuitemaker, H., Correlations between HIV-1 clades and HIV-1

antibody neutralization sensitivity: significant for vaccine development? (2010) Current HIV Research 8:579-586.

Wahren, B., Biswas, P., Borggren, M., Coleman, A., da Costa, K., De Haes, W., Dieltjens, T., Dispinseri, S., Grupping, K., Hallengard, D., Hornig, J., Klein, K., Mainetti, L., Palma, P., Reudelsterz, M., Seifried, J., Selhorst, P., Skold, A., van Gils, M.J., Weber, C., Shattock,

R., and Scarlatti, G., Rational Design of HIV Vaccine and Microbicides: Report of the EUROPRISE Annual Conference. (2010) Journal of Translational Medicine 8:72.

Edo-Matas, D., van Gils, M.J., Bowles, E.J., Navis, M., Rachinger, A., Boeser-Nunnink, B.,

Stewart-Jones, G.B., Kootstra, N.A., Wout, A.B., and Schuitemaker, H., Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. (2010) Virology 405:492-504.

Euler, Z., van Gils, M.J., Bunnik, E.M., Phung, P., Schweighardt, B., Wrin, T., and

Schuitemaker, H., Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. (2010) Journal of Infectious Diseases 201:1045-1053.

van Gils, M.J., Bunnik, E.M., Burger, J.A., Jacob, Y., Schweighardt, B., Wrin, T., and

Schuitemaker, H., Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. (2010) Journal of Virology 84:3576-3585.

(3)

263

Bunnik, E.M., van Gils, M.J., Lobbrecht, M.S., Pisas, L., Nanlohy, N.M., van, B.D., van

Nuenen, A.C., Hessell, A.J., and Schuitemaker, H., Emergence of b12 resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure. (2010) Journal of General Virology 91:1365-1372.

van Gils, M.J., Edo-Matas, D., Schweighardt, B., Wrin, T., and Schuitemaker, H., High

Prevalence of Neutralizing Activity against Multiple Unrelated HIV-1 Subtype B Variants in Sera from HIV-1 Subtype B Infected Individuals: Evidence for Subtype Specific Rather than Strain Specific Neutralizing Activity. (2010) Journal of General Virology 91:250-258.

van Gils, M.J., Euler, Z., Schweighardt, B., Wrin, T., and Schuitemaker, H., Prevalence

of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. (2009) AIDS 23:2405-2414.

Bunnik, E.M., van Gils, M.J., Lobbrecht, M.S., Pisas, L., van Nuenen, A.C., and Schuitemaker,

H., Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. (2009) Virology 390:348-355.

van de Bovenkamp, M., Groothuis, G.M., Draaisma, A.L., Merema, M.T., Bezuijen, J.I.,

van Gils, M.J., Meijer, D.K., Friedman, S.L., Olinga, P., Precision-cut liver slices as a new

model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. (2005) Toxicological Sciences 85:632-638.

Referenties

GERELATEERDE DOCUMENTEN

Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to

therefore the ability of TAFIa to remove C-teminal lysine residues from partially degraded fibrin is abrogated. The biological significance of the TAFI degradation

Thrombin-Activatable Fibrinolysis inhibitor (TAFI) binds to collagen-like proteins SclA and SclB at the surface of S.. Activation of TAFI at this surface redirects inflammation from

pyogenes dissemination, we compared the bacterial load in spleen, kidney, lung, liver and blood of TAFI humanized and wild-type mice after 24 and 48 h of initiation of

Histopathology examination of kidney, liver and lung from infected wild-type and TAFI-KO mice during the 5-day infection showed no relevant changes compared to the

pyogenes infection of mice expressing human TAFI (chapter 5).. To this end, mice expressing only human TAFI were generated and infected with

pyogenes werd duidelijk dat de humaan TAFI expresserende muizen in vergelijking met normale muizen veel gevoeliger waren voor infectie wat leidde tot een verhoogde

Marcel Schouten, thank you for dedicating your time to help me with setting up the animal experiments.. From the (Neuro)Pathology department: Rene Sersansie and